EZH2 and cancer: In addition to being critical for the maintenance of various cancers, EZH2 has also been shown to exert a tumour‐suppressive function: loss‐of‐function mutations in many PRC2 members are prevalent in various cancers, and mouse models deficient for EZH2 or other PRC2 components show cancer predisposition 18, 82.